Ignatov, Tanja and Gorbunow, Franceska and Eggemann, Holm and Ortmann, Olaf and Ignatov, Atanas (2019) Loss of HER2 after HER2-targeted treatment. BREAST CANCER RESEARCH AND TREATMENT, 175 (2). pp. 401-408. ISSN 0167-6806, 1573-7217
Full text not available from this repository. (Request a copy)Abstract
PurposeHER2 expression has been reported to be discordant between primary tumor and metastatic tissue.Patients and methodsHER2 discordance and relation to HER2-targeted treatment was investigated in 227 patients with primary breast cancer.ResultsHER2 discordance between primary biopsy and second biopsy after neoadjuvant or adjuvant treatment was observed in 20.7%. This discordance was related only to the use of HER2-targeted treatment: 30 of 33 (90.9%) women with downgraded HER2 expression underwent a HER2-targeted therapy, whereas in the group of patients with concordant HER2 expression, only 32 of 180 (17.8%) received HER2-targeted treatment (p<0.0001). HER2 discordance was associated with reduced disease-free survival but not overall survival. In a second cohort, including patients with HER2 overexpressing tumors, trastuzumab treatment was associated with change of HER2 expression from positive to negative in 47.3% of cases. Addition of pertuzumab increased the rate of HER2 loss up to 63.2%. Notably, the interval between last HER2-targeted treatment and the time of surgical excision of the tumor after neoadjuvant chemotherapy (NACT) or the biopsy of the metachronous metastasis was associated with a significant change in HER2 expression. The median time between NACT and the time of surgical excision was 23 days (range 5-81 days) for tumors with decreased HER2 expression and 51 days (range 10-179 days) for tumors with concordant HER2 expression. Furthermore, median time between the end of adjuvant treatment and second histology of the metachronous metastases accounted for 15 days (range 2-165 days) and 478 days (range 7-2739 days) was observed in the group of patients with decreased or unchanged HER2 expression, respectively.ConclusionThe interval between anti-HER2 treatment and the determination of HER2 in second histology is strongly associated with HER2 expression.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | HORMONE-RECEPTOR STATUS; BREAST-CANCER; NEOADJUVANT CHEMOTHERAPY; DOWN-REGULATION; EXPRESSION; TRASTUZUMAB; PROGESTERONE; PERTUZUMAB; ESTROGEN; ERBB2; Trastuzumab; Breast cancer; HER2 |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Frauenheilkunde und Geburtshilfe (Schwerpunkt Frauenheilkunde) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 14 Apr 2020 09:09 |
| Last Modified: | 14 Apr 2020 09:09 |
| URI: | https://pred.uni-regensburg.de/id/eprint/26940 |
Actions (login required)
 |
View Item |
